Just reported
From Merck's results release of 29 de octubre de 2026; its quarterly report has since been filed.
Actual
18,09B US$
+4,7 % y/y
+8,9 % q/q
Guided
—
No guide given
Actual
2,04 US$
-12 % y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Merck is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Los porcentajes de ingresos son estimaciones para FY2025, no cifras de un informe oficial.
Keytruda and Keytruda Qlex
Cancer medicines. Keytruda is given into a vein; Keytruda Qlex is a form given as an injection under the skin.
Gardasil and Gardasil 9
Vaccines that help prevent certain cancers and other diseases caused by some types of human papillomavirus.
Januvia and Janumet
Prescription medicines used to help lower blood sugar in adults with type 2 diabetes.
Winrevair
A medicine for adults with pulmonary arterial hypertension, a disease that raises blood pressure in the arteries from the heart to the lungs.
Lipfendra
An oral medicine used with diet and exercise to lower low-density lipoprotein cholesterol in adults with high cholesterol.
Bravecto
A range of medicines that protect dogs and cats against fleas and ticks, including oral, topical and injectable forms.
Estados financieros completos →
Merck discovers, develops, manufactures and sells prescription medicines and vaccines for people, including cancer treatments such as Keytruda and vaccines such as Gardasil. Its Animal Health business sells medicines, vaccines and animal identification and monitoring products to veterinarians, farmers and other animal-care businesses.
Construido a partir de los propios informes de Merck & Co., Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
147,76 US$+0,6 %cierre 13 nov
Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 4 de noviembre de 2026
Merck makes prescription medicines and vaccines for people, and medicines, vaccines and monitoring products for animals.
Grade A
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 41 trimestres del historial de calificaciones de Merck & Co., Inc.. Los otros 39 llegan hasta noviembre de 2016.